https://www.lonruconsulting.com/blog-1-1 daily 0.75 2026-04-01 https://www.lonruconsulting.com/blog-1-1/why-your-ai-pilot-is-failing-the-missing-agentic-layer monthly 0.5 2026-04-01 https://www.lonruconsulting.com/blog-1-1/stop-buying-strategy-you-cant-execute-the-value-of-the-builder-consultant monthly 0.5 2026-03-25 https://www.lonruconsulting.com/blog-1-1/deploying-a-cgt-is-hard-enough-why-are-hospitals-still-tracking-patient-journeys-on-disparate-tools monthly 0.5 2026-03-18 https://www.lonruconsulting.com/blog-1-1/accelerating-diy-with-ai-a-lonr-lens-side-quest-for-the-gemini-live-agent-challenge monthly 0.5 2026-03-16 https://images.squarespace-cdn.com/content/v1/6773457e9d31f15685a3f15f/b4d8b7f4-2140-4551-a37f-2b3507688a14/handymate_architecture.png Lonrú Newsletter - Accelerating DIY with AI - A Lonrú Lens Side Quest for the Gemini Live Agent Challenge - Make it stand out HandyMate architecture demonstrates what may be possible when live agents are deployed in cell and gene therapy workflows. https://www.lonruconsulting.com/blog-1-1/the-end-of-the-vanity-facility-why-cgt-manufacturing-strategy-requires-active-architecture monthly 0.5 2026-03-11 https://www.lonruconsulting.com/blog-1-1/effective-due-diligence-requires-active-architecture monthly 0.5 2026-03-04 https://www.lonruconsulting.com/blog-1-1/abc-1 monthly 0.5 2026-02-25 https://www.lonruconsulting.com/blog-1-1/stop-pitching-features-start-calculating-cogs-the-b2b-sales-engine-for-bioprocessing monthly 0.5 2026-02-18 https://www.lonruconsulting.com/blog-1-1/abc monthly 0.5 2026-02-11 https://www.lonruconsulting.com/blog-1-1/the-cost-of-yes-why-strategic-dilution-is-killing-your-innovation-pipeline monthly 0.5 2026-02-04 https://www.lonruconsulting.com/blog-1-1/beyond-the-repository-transforming-contracts-into-active-risk-intelligence monthly 0.5 2026-01-28 https://www.lonruconsulting.com/blog-1-1/test monthly 0.5 2026-01-21 https://www.lonruconsulting.com/blog-1-1/operational-latency-solving-the-structural-gap-between-strategy-and-execution monthly 0.5 2026-01-14 https://www.lonruconsulting.com/blog-1-1/escaping-pilot-purgatory-why-2025-was-the-year-of-the-builder monthly 0.5 2026-01-07 https://images.squarespace-cdn.com/content/v1/6773457e9d31f15685a3f15f/4aeeddb1-d13a-495d-97fa-db2e7a7afab3/LL2026ko.png Lonrú Newsletter - Escaping AI Pilot Purgatory: Why 2025 Was the Year of the Builder - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.lonruconsulting.com/blog-1-1/talking-turkey-how-cgt-enabling-technologies-could-strengthen-future-biosecurity monthly 0.5 2025-11-25 https://www.lonruconsulting.com/blog-1-1/are-you-post-approval-ready-what-the-fdas-new-guidance-means-for-cgt-enabling-technology-providers monthly 0.5 2025-11-18 https://www.lonruconsulting.com/blog-1-1/how-public-private-partnerships-are-shaping-global-cell-amp-gene-therapy monthly 0.5 2025-11-05 https://www.lonruconsulting.com/blog-1-1/from-europes-evidence-framework-to-the-us-commercial-opportunity-in-cgt monthly 0.5 2025-10-29 https://www.lonruconsulting.com/blog-1-1/mapping-the-approval-landscape-of-europes-cell-amp-gene-therapies monthly 0.5 2025-10-22 https://www.lonruconsulting.com/blog-1-1/how-advanced-therapy-treatment-centre-networks-enable-national-delivery-of-cell-and-gene-therapies monthly 0.5 2025-10-16 https://www.lonruconsulting.com/blog-1-1/europes-next-translation-mapping-the-networks-behind-cell-and-gene-therapy monthly 0.5 2025-10-08 https://www.lonruconsulting.com/blog-1-1/2025-investment-signal-heatmap-a-snapshot-of-cell-and-gene-therapy monthly 0.5 2025-10-01 https://www.lonruconsulting.com/blog-1-1/rna-x-cell-and-gene-therapy-illuminating-the-intersections monthly 0.5 2025-09-24 https://www.lonruconsulting.com/blog-1-1/irelands-cell-and-gene-therapy-map-illuminating-the-islands-growing-ecosystem monthly 0.5 2025-09-17 https://www.lonruconsulting.com/blog-1-1/crispr-clinical-trials-global-shifts-and-new-directions monthly 0.5 2025-09-10 https://www.lonruconsulting.com/blog-1-1/the-arc-of-innovation-in-cell-amp-gene-therapy-a-decade-of-milestones-and-signals-ahead monthly 0.5 2025-09-03 https://www.lonruconsulting.com/blog-1-1/v8s5z6q8zeenohbmyb1y2q0plqd3vy monthly 0.5 2025-08-27 https://www.lonruconsulting.com/blog-1-1/the-business-of-reaching-patients-esgct-2025-preview monthly 0.5 2025-08-20 https://www.lonruconsulting.com/blog-1-1/crispr-safety-where-tools-companies-can-lead monthly 0.5 2025-08-13 https://images.squarespace-cdn.com/content/v1/6773457e9d31f15685a3f15f/5cb95a05-d922-47bc-a9b4-1dcd875c23ee/Lonru%CC%81+Consulting_Generic+Introduction+to+Services.png Lonrú Newsletter - CRISPR Safety: Where Tools Companies Can Lead - Make it stand out The recent review by Toofan et al. outlines six key safety considerations for CRISPR/Cas editing, we outline opportunities for tools companies to address each point. https://www.lonruconsulting.com/blog-1-1/a-global-view-on-point-of-care-manufacturing-regulations-after-the-uks-leap monthly 0.5 2025-08-06 https://images.squarespace-cdn.com/content/v1/6773457e9d31f15685a3f15f/7a5c3e42-ed1d-4264-805f-1ac206673e71/LL+POC+Banner.png Lonrú Newsletter - A global view on point of care manufacturing regulations after the UK’s leap - Make it stand out Bringing the factory to the patient: we’re tracking the rules that make it possible. https://www.lonruconsulting.com/blog-1-1/mhras-pointofcare-manufacturing-framework monthly 0.5 2025-07-30 https://images.squarespace-cdn.com/content/v1/6773457e9d31f15685a3f15f/3ebbd002-8c84-4133-9056-9d4f4efff17d/MHRA+POC+MFG+Image.png Lonrú Newsletter - MHRA’s Point‑of‑Care Manufacturing Framework - Make it stand out The UK’s MHRA unveils first-of-its-kind framework allowing hospitals to manufacture personalized cell and gene therapies on-site. https://www.lonruconsulting.com/blog-1-1/beyond-npv-quantifying-patient-benefit-in-cell-amp-gene-therapies monthly 0.5 2025-07-22 https://images.squarespace-cdn.com/content/v1/6773457e9d31f15685a3f15f/34d2bc62-e5e3-44d3-b622-062fda7f8a4b/Drivers.png Lonrú Newsletter - Beyond NPV: Quantifying Patient Benefit in Cell & Gene Therapies - Make it stand out Table 1. Financial levers dominate NPV calculations, whereas disease burden and probability estimates dominate SALY/SADY making the two metrics complementary rather than redundant. https://images.squarespace-cdn.com/content/v1/6773457e9d31f15685a3f15f/b22f4afe-9e9e-43f7-8ca0-1c53a171d9bb/SALY+SADY+Table.png Lonrú Newsletter - Beyond NPV: Quantifying Patient Benefit in Cell & Gene Therapies - Make it stand out Table 2. Annual Science-Adjusted Life-Years (SALYs) and Science-Adjusted Disability-Years (SADYs) for representative therapeutics spanning Brainin’s original examples and a selection of cell- and gene-therapy (CGT) assets† † Incident U.S. patient population, mirroring Brainin’s convention. § Birth prevalence ≈ 1 : 2,024 (CDC) → ~1,830 births / yr; halving to those with ≥ 2 VOCs ⇒ 1,350. ¶ U.S. annual DMD diagnoses estimated at 300–400 boys / yr (1 : 5 000 male births). †† CDC reports just over 18,000 youth diagnosed with T1D each year. ‡‡ FA affects 1/50,000 people; 4 M births × 1/50,000 ⇒ ~80 births; 60 % meet cardiac-gene-therapy criteria ⇒ ~50. §§ GenSight estimates 15,000–20,000 new RP vision-loss cases per year in the US + EU; mid-point used for US. https://www.lonruconsulting.com/blog-1-1/paving-the-pediatric-crispr-infrastructure monthly 0.5 2025-07-16 https://images.squarespace-cdn.com/content/v1/6773457e9d31f15685a3f15f/8707f184-7c5c-4608-95de-6ee1849e4441/Highway.png Lonrú Newsletter - Bridging The Data Gap On The Pediatric CRISPR Highway - Make it stand out Figure 1: Blueprint of the “next-gen” CRISPR-cure highway: from patient intake, through rapid design and micro-factory production, into a secure cloud backbone that feeds real-world evidence back to the very first node. https://images.squarespace-cdn.com/content/v1/6773457e9d31f15685a3f15f/49dd509b-22ea-4156-aa88-4326602fcc07/Lonru%CC%81+CRISPR.png Lonrú Newsletter - Bridging The Data Gap On The Pediatric CRISPR Highway - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.lonruconsulting.com/blog-1-1/who-follows-verve monthly 0.5 2025-07-09 https://images.squarespace-cdn.com/content/v1/6773457e9d31f15685a3f15f/ab4d838c-8ec1-4cc3-a058-462b37432a7d/Sponsor+programs+and+indications.png Lonrú Newsletter - Who Follows Verve? - Make it stand out Source: Lonrú Consulting’s VantagePoint™ analysis, July 2025. The post-Verve field of clinical-stage gene-editors and where each sits on the white space v second wave spectrum. https://images.squarespace-cdn.com/content/v1/6773457e9d31f15685a3f15f/6cf7a8e7-c8ea-47fb-88cb-eb32f106ed1e/Gene-Editing+Players+Runway+vs+Indication+Market+Size.png Lonrú Newsletter - Who Follows Verve? - Make it stand out Source: Lonrú Consulting’s VantagePoint™ analysis (July 2025). Cash-runway figures drawn from latest SEC filings; 2030 market sizes from consensus analyst and disease-area forecasts. https://www.lonruconsulting.com/blog-1-1/from-pipeline-fillers-to-platform-plays monthly 0.5 2025-07-01 https://images.squarespace-cdn.com/content/v1/6773457e9d31f15685a3f15f/a4c9a4df-30f5-4b41-a5ea-847978886136/Lonru%CC%81+Lens+-+Capstan+Verve+Prime+AbbVie+and+BMS.jpg Lonrú Newsletter - From Pipeline Fillers to Platform Plays - Make it stand out One size doesn’t fit all: each CGT platform archetype carries its own toolbox. https://images.squarespace-cdn.com/content/v1/6773457e9d31f15685a3f15f/effefbb9-b0bb-4f3d-8537-4d268d9b0715/Lonru%CC%81+Lens+-+Capstan+Verve+Prime+AbbVie+and+BMS+2.png Lonrú Newsletter - From Pipeline Fillers to Platform Plays - Make it stand out Three emerging CGT platform engines: in-vivo programmable cell therapy, systemic base editing and ex-vivo prime editing - ready to power a decade of multi-asset pipelines. https://www.lonruconsulting.com/blog-1-1/the-non-viral-deliverysurge-lnpsextracellularvesiclesamp-the-emerging-pipeline-in-cellampgene-therapy monthly 0.5 2025-06-25 https://images.squarespace-cdn.com/content/v1/6773457e9d31f15685a3f15f/a4ed5b5a-5168-4b32-89f6-c55f30b6ed26/LNP+-+liver+target.png Lonrú Newsletter - The Non-Viral Delivery Surge: LNPs, Extracellular Vesicles & the Emerging Pipeline in Cell & Gene Therapy - Make it stand out Figure 1 | From syringe to hepatocyte in one step. A single intravenous dose of ionizable-lipid nanoparticles (LNPs) delivers base-editing RNA directly to the liver, bypassing ex-vivo manipulation and shortening the therapeutic chain to needle-to-target. https://www.lonruconsulting.com/blog-1-1/from-bottleneck-to-backbone-building-the-us-interventional-genetics-interstate monthly 0.5 2025-06-11 https://images.squarespace-cdn.com/content/v1/6773457e9d31f15685a3f15f/d1080292-3d90-41bd-a429-f8b7f63f1ac8/Interventional-Genetics+Interstate.png Lonrú Newsletter - From Bottleneck to Backbone: Building the U.S. “Interventional-Genetics Interstate” - Make it stand out Investing in nimble, connected manufacturing infrastructure today paves an Interventional-Genetics Interstate that will shorten timelines, cut costs and most importantly get transformative treatments to rare-disease patients faster. https://www.lonruconsulting.com/blog-1-1/reflections-from-asgct-2025 monthly 0.5 2025-07-09 https://images.squarespace-cdn.com/content/v1/6773457e9d31f15685a3f15f/08533f09-7ff4-4447-95f4-82db0d51ac7c/ChatGPT+Image+May+17%2C+2025%2C+06_41_54+PM.png Lonrú Newsletter - Reflections from ASGCT 2025 - Make it stand out A breakthrough worth noting: an n-of-1 gene-editing therapy. Let’s celebrate the science, but keep patients and their families front-of-mind and proceed with care as we work to reform the business model. https://www.lonruconsulting.com/blog-1-1/how-patient-led-business-models-are-accelerating-the-next-wave-of-cell-amp-gene-therapies monthly 0.5 2025-05-13 https://images.squarespace-cdn.com/content/v1/6773457e9d31f15685a3f15f/737cc5d5-8ff1-46c3-9349-403a83082ee8/Infographic+-+Patient-Led+Innovations+%281%29.jpg Lonrú Newsletter - How patient-led business models are accelerating the next wave of cell & gene therapies - Make it stand out Where patient advocacy becomes the catalyst for next-gen cell & gene therapies. https://images.squarespace-cdn.com/content/v1/6773457e9d31f15685a3f15f/b3c11947-e545-48fe-89ef-4a65f2d19b40/Infographic+-+Patient-Led+Innovations+-+Vantagepoint.jpg Lonrú Newsletter - How patient-led business models are accelerating the next wave of cell & gene therapies - Make it stand out Illuminating the route from patient-driven discovery to scalable market success. https://www.lonruconsulting.com/blog-1-1/through-the-lonr-lens-what-to-watch-at-asgct-2025 monthly 0.5 2025-05-08 https://images.squarespace-cdn.com/content/v1/6773457e9d31f15685a3f15f/5ae2a9b4-ac9a-499b-a02b-cfe23606b228/5+Key+Themes+Emerging+in+NOLA.png Lonrú Newsletter - Through the Lonrú Lens – What to Watch at ASGCT 2025 - Make it stand out Talk Hotspots: Top 5 Topics at ASGCT 2025 https://images.squarespace-cdn.com/content/v1/6773457e9d31f15685a3f15f/1d6b9f9b-e94e-404c-8382-da7820dc91af/Topics+by+numbers.png Lonrú Newsletter - Through the Lonrú Lens – What to Watch at ASGCT 2025 - Make it stand out Four Trends Shaping ASGCT 2025 https://www.lonruconsulting.com/blog-1-1/meeting-on-the-med-a-pulse-check-on-cgt monthly 0.5 2025-04-23 https://images.squarespace-cdn.com/content/v1/6773457e9d31f15685a3f15f/b1c81f9d-9a16-455e-817c-c0337b5dad55/CN220425_LonruLens.jpg Lonrú Newsletter - Meeting on the Med: a pulse check on CGT - Make it stand out Dr Caoimhe Nic An tSaoir, PhD MBA representing Lonrú Consulting at its first ARM Meeting on the Med—illuminating innovation in Rome. https://www.lonruconsulting.com/blog-1-1/unlocking-cell-and-gene-therapies-introducing-vantagepoint-lonr-consultings-unified-suite-of-strategic-solutions monthly 0.5 2025-04-02 https://images.squarespace-cdn.com/content/v1/6773457e9d31f15685a3f15f/a21236b5-38f1-419b-a8c3-b4f82135efbd/VantagePoint+6+Services.png Lonrú Newsletter - Unlocking Cell and Gene Therapies: Introducing VantagePoint™ – Lonrú Consulting’s Suite of Solutions For Growth - Make it stand out Lonrú Consulting’s VantagePoint™: A Unified Suite of AI-powered Solutions Propelling Enabling Technology Companies at Every Stage of Growth. https://www.lonruconsulting.com/blog-1-1/navigating-strategic-partnerships-how-platform-technology-providers-can-overcome-validation-challenges monthly 0.5 2025-03-26 https://images.squarespace-cdn.com/content/v1/6773457e9d31f15685a3f15f/1742989359619-TNG0V40EPHL5UB4GJM96/unsplash-image-Q1p7bh3SHj8.jpg Lonrú Newsletter - Navigating Strategic Partnerships: How Platform Technology Providers Can Overcome Validation Challenges - Make it stand out Launching Lonrú's VantagePoint™ Validation Platform: Illuminating strategic clarity for enabling technology companies in Cell & Gene Therapy. https://www.lonruconsulting.com/blog-1-1/catalysing-the-cogs-revolution-the-role-of-enabling-technologies-in-cgt monthly 0.5 2025-03-19 https://www.lonruconsulting.com/blog-1-1/illuminating-crispr-clinical-trial-progress-a-lonr-lens-for-enabling-tools-providers monthly 0.5 2025-03-12 https://www.lonruconsulting.com/blog-1-1/bridging-the-gapenabling-technology-providers-amp-the-path-to-the-clinic monthly 0.5 2025-03-05 https://images.squarespace-cdn.com/content/v1/6773457e9d31f15685a3f15f/663b1501-d96d-49d8-9f4c-6ecac85dc20d/70x90cm+Poster_CNAT_Keystone.png Lonrú Newsletter - Bridging the Gap—Enabling Technology Providers & the Path to the Clinic - Make it stand out Lonrú’s full report, poster and decision tree framework are available for download. https://www.lonruconsulting.com/blog-1-1/lonr-at-keystone-precision-genome-engineering-and-the-future-of-crispr-clinical-translation monthly 0.5 2025-02-26 https://images.squarespace-cdn.com/content/v1/6773457e9d31f15685a3f15f/098e9954-e709-41d5-99ee-ae3ccf6ea51e/Keystone+Conference.jpg Lonrú Newsletter - Lonrú at Keystone: Precision Genome Engineering and the Future of CRISPR Clinical Translation - Make it stand out Lonrú’s poster evaluates global regulatory trends and identifies common pitfalls in IND/CTA submissions that lead to clinical holds and delays, we also introduce our decision tree framework, a tool to help developers navigate common pitfalls. https://www.lonruconsulting.com/blog-1-1/how-the-focus-of-cell-and-gene-clinical-trials-in-the-uk-is-shifting monthly 0.5 2025-02-24 https://images.squarespace-cdn.com/content/v1/6773457e9d31f15685a3f15f/44b5d80c-0a88-4ebf-8e4c-4b47dca48d6d/Screenshot+2025-02-18+at+19.13.16.png Lonrú Newsletter - How the Focus of Cell and Gene Clinical Trials in the UK is Shifting - Make it stand out Explore Lonrú’s interactive dashboard examples to view UK CGT trial trends for further insights. https://images.squarespace-cdn.com/content/v1/6773457e9d31f15685a3f15f/36d733e2-c75a-4f47-8066-534f911e0537/output+%286%29.png Lonrú Newsletter - How the Focus of Cell and Gene Clinical Trials in the UK is Shifting - Make it stand out By categorizing CGT clinical trials into broader therapeutic areas, we can see shifts in industry focus. https://www.lonruconsulting.com/blog-1-1/the-critical-role-of-academic-translational-centers-in-advancing-cell-and-gene-therapies monthly 0.5 2025-02-12 https://images.squarespace-cdn.com/content/v1/6773457e9d31f15685a3f15f/1739272945090-5YM8L4NSO5R6NNXFGFBT/unsplash-image-RlOAwXt2fEA.jpg Lonrú Newsletter - The Critical Role of Academic Translational Centers in Advancing Cell and Gene Therapies - Make it stand out Without vital support, translational momentum is at risk—academic labs remain the backbone of cell and gene therapy innovation, but funding challenges threaten to slow progress from discovery to patient impact. https://www.lonruconsulting.com/blog-1-1/building-an-all-island-cgt-strategy-irelands-opportunity-to-deliver-cell-and-gene-therapy monthly 0.5 2025-02-05 https://images.squarespace-cdn.com/content/v1/6773457e9d31f15685a3f15f/1738690902268-F8X5TXMWMCJX9JI0OJBU/unsplash-image-OrwkD-iWgqg.jpg Lonrú Newsletter - Building an All-Island CGT Strategy: Ireland’s Opportunity to Deliver Cell and Gene Therapy - Make it stand out CGT Ecosystems: Ireland Has The Opportunity To Build From The Ground Up. https://www.lonruconsulting.com/blog-1-1/de-risking-cell-and-gene-therapy-development-global-regulatory-strategies-for-streamlined-development monthly 0.5 2025-01-28 https://images.squarespace-cdn.com/content/v1/6773457e9d31f15685a3f15f/67aacae0-65b7-4212-9ddf-5e447d8596a3/FDA+approvals+and+pipeline+2025+PBLi+no+gridlines_transparent.png Lonrú Newsletter - De-risking Cell and Gene Therapy Development: Global Regulatory Strategies for Streamlined Development - Make it stand out Figure 1. Showing FDA-approved and pipeline cell and gene therapies. https://www.lonruconsulting.com/blog-1-1/from-semiconductors-to-genes-engineering-precision-in-advanced-therapies monthly 0.5 2025-01-23 https://images.squarespace-cdn.com/content/v1/6773457e9d31f15685a3f15f/dd1ddb12-1f5e-496c-b282-dc6b15b30464/Semi+conductor.png Lonrú Newsletter - From Semiconductors to Genes: Engineering Precision in Advanced Therapies - Make it stand out Precision at the Molecular Level: Lessons from Semiconductors for the Future of Cell and Gene Therapy https://www.lonruconsulting.com/blog-1-1/illuminating-the-future-of-cell-and-gene-therapies monthly 0.5 2025-01-23 https://images.squarespace-cdn.com/content/v1/6773457e9d31f15685a3f15f/fc123fcb-cf1f-41be-98b8-1fc72ad55996/Capital+Markets+and+Commercial+Insights Lonrú Newsletter - Illuminating the Future of Cell and Gene Therapies - Make it stand out ARM’s State of the Industry Briefing: Panelists discussing capital markets and commercial insights. https://www.lonruconsulting.com/blog-1-1/charting-the-trajectory-of-cell-and-gene-therapy-from-2024-to-2025 monthly 0.5 2025-01-13 https://www.lonruconsulting.com/blog-1-1/introducing-lonr-consulting monthly 0.5 2025-01-08 https://images.squarespace-cdn.com/content/v1/6773457e9d31f15685a3f15f/ab377f7c-295f-448d-a764-5f8fd4a11513/Introducing+Lonru%CC%81+Consulting+Blog+Banner.png Lonrú Newsletter - Introducing Lonrú Consulting - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.lonruconsulting.com/contact daily 0.75 2025-12-30 https://images.squarespace-cdn.com/content/v1/6773457e9d31f15685a3f15f/1735830343342-Z0W5O64W3IF7YDFPF6FO/unsplash-image--J2OKQquFF0.jpg https://www.lonruconsulting.com/about daily 0.75 2025-12-30 https://images.squarespace-cdn.com/content/v1/6773457e9d31f15685a3f15f/bafae65d-929b-4ed0-bd88-70774ae56aba/caoimhe-jess-lowe-photography-42.jpg https://www.lonruconsulting.com/home daily 1.0 2025-12-30 https://images.squarespace-cdn.com/content/v1/6773457e9d31f15685a3f15f/25d701a9-1d16-4aef-b71b-a51d2df10a84/unsplash-image-cuEpo721ACY.jpg https://images.squarespace-cdn.com/content/v1/6773457e9d31f15685a3f15f/7477ea44-7fc8-4e2e-bd5f-b963ce26a97d/2026+Logo%2C+company+name+and+tagline.png https://images.squarespace-cdn.com/content/v1/6773457e9d31f15685a3f15f/51c25a99-5bc7-4bab-8747-f11fadc3dedc/2026+Logo+Exploder.png https://www.lonruconsulting.com/services-5 daily 0.75 2025-12-30 https://images.squarespace-cdn.com/content/v1/5ec321c2af33de48734cc929/1618497259178-6XJGK9GR6YAVBQL5L519/20140301_Trade-151_012-2.jpg Lonrú Consulting Services https://images.squarespace-cdn.com/content/v1/5ec321c2af33de48734cc929/1607694583486-2PQT0LQ193RL7MCB6DX4/20140228_Trade+151_0046.jpg Lonrú Consulting Services https://images.squarespace-cdn.com/content/v1/6773457e9d31f15685a3f15f/6e647a9c-399e-4eb7-b9b2-fb099181a5a0/caoimhe-jess-lowe-photography-48.jpg https://www.lonruconsulting.com/vantagepoint-interactive-dashboards-1 daily 0.75 2025-12-30 https://www.lonruconsulting.com/clientpage-1 daily 0.75 2026-02-10 https://www.lonruconsulting.com/nameclientpage-2 daily 0.75 2026-02-10